<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01551615</url>
  </required_header>
  <id_info>
    <org_study_id>D4200C00102</org_study_id>
    <nct_id>NCT01551615</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With Vandetanib</brief_title>
  <acronym>Vandetanib</acronym>
  <official_title>A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Metformin, an OCT2 Substrate, in Healthy Subjects When Administered Alone and in Combination With a Single Oral Dose of Vandetanib (CAPRELSA) 800 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Study in Healthy Volunteers to Assess the Pharmacokinetics of Metformin Administered Alone
      and In Combination with Vandetanib
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Metformin, an
      OCT2 Substrate, in Healthy Subjects When administered Alone and in Combination with a Single
      Oral Dose of Vandetanib (CAPRELSA) 800 mg
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC for metformin administered alone and in combination with vandetanib 800 mg</measure>
    <time_frame>Period 1: Predose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 32, 40, 48, 60, 72, and 96 hours post dose. Period 2: pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 32, 40, 48, 60, 72, and 96 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for metformin administered alone and in combination with vandetanib 800 mg</measure>
    <time_frame>Period 1: Predose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 32, 40, 48, 60, 72, and 96 hours post dose. Period 2: pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 32, 40, 48, 60, 72, and 96 hours post-dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Treatment period 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG data</measure>
    <time_frame>Treatment period 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory data</measure>
    <time_frame>Treatment period 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs data</measure>
    <time_frame>Treatment period 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK parameters for metformin administered alone and in combination with vandetanib 800 mg</measure>
    <time_frame>Period 1: Predose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 32, 40, 48, 60, 72, and 96 hours post dose. Period 2: pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 32, 40, 48, 60, 72, and 96 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vandetanib PK parameters for vandetanib in combination with metformin</measure>
    <time_frame>Period 2: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36, 48, 72, 96, 168, 240, 336, 504, and 672 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for metformin in urine when administered alone and in combination with vandetanib</measure>
    <time_frame>Period 1: Day 1, 0 to 24 hrs and 24 to 48 hrs post metformin dose. Period 2: Day 1, 0 to 24 hrs and 24 to 48 hrs post metformin dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Metformin then metformin + vandetanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin alone followed by metformin in combination with vandetanib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 1000 mg</intervention_name>
    <description>2 x 500 mg oral tablets</description>
    <arm_group_label>Metformin then metformin + vandetanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib 800 mg</intervention_name>
    <description>2 x 300 mg and 2 x 100 mg oral tablets</description>
    <arm_group_label>Metformin then metformin + vandetanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females aged 18 to 50 years with a weight of at least 50 kg and a
             body mass index between 18 and 30 kg/m2 inclusive.

          -  Females must have a negative pregnancy test at screening, must not be lactating and
             must be of non-childbearing potential.

          -  Volunteers will be wild type for the OCT2 gene (as tested for within the last 6 months
             prior to Day 1 in Period 1)

        Exclusion Criteria:

          -  History or presence of gastrointestinal, hepatic, or renal disease or any medically
             significant disorder.

          -  History of or ongoing severe allergy/hypersensitivity to drugs with a similar chemical
             structure or class to vandetanib or metformin.

          -  Volunteers who smoke more than 5 cigarettes per day or are unable to refrain from
             smoking while resident in the study center.

          -  Known or suspected history of drug abuse.

          -  Screening supine blood pressure of greater than 140/90 mmHg and/or a resting heart
             rate of less than 45 beats per minute.

          -  Clinically significant current active skin disease (eg moderate to severe acne,
             psoriasis, eczema).

          -  Any positive result on screening for serum hepatitis B, surface antigen, hepatitis C
             antibody, and human immunodeficiency virus (HIV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1437&amp;filename=CSR-D4200C00102.pdf</url>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1437&amp;filename=CSR-D4200C00102.pdf</url>
    <description>CSR-D4200C00102.pdf</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1437&amp;filename=D4200C00102_Revised_CSP_redacted.pdf</url>
    <description>Revised_CSP_redacted</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>vandetanib</keyword>
  <keyword>metformin</keyword>
  <keyword>AUC(0-t)</keyword>
  <keyword>t1/2</keyword>
  <keyword>tmax</keyword>
  <keyword>CL/F</keyword>
  <keyword>Vz/F</keyword>
  <keyword>Cmax</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

